Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2009 by Sheba Medical Center.
Recruitment status was:  Recruiting
Information provided by:
Sheba Medical Center Identifier:
First received: May 30, 2007
Last updated: March 24, 2009
Last verified: March 2009

In this study we intend to compare the effect of Sertindole to that of Risperidone on cognitive impairment in schizophrenia.

Hypothesis: Sertindole will be as effective as Risperidone for treating cognitive impairment in schizophrenia and with fewer side effects.

Condition Intervention Phase
Drug: Sertindole
Drug: Risperidone
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone

Resource links provided by NLM:

Further study details as provided by Sheba Medical Center:

Primary Outcome Measures:
  • cognitive functioning [ Time Frame: 24 weeks ]

Secondary Outcome Measures:
  • Discontinuation due to all causes, symptomatology and adverse events. [ Time Frame: 24 weeks ]

Estimated Enrollment: 60
Study Start Date: October 2008
Estimated Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sertindole Drug: Sertindole
Oral (tablets), 16-24 mg QD (once a day) for 12 weeks.
Other Name: Serdolect
Active Comparator: Risperidone Drug: Risperidone
Oral (tablets), 4-8 mg QD (once a day) for 12 weeks.
Other Names:
  • Rispond
  • Risperdal
  • Risperidex

  Show Detailed Description


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients suffering from Schizophrenia (DSM IV).
  • Failure of at least one previous antipsychotic for intolerance.
  • Psychotic symptoms that are not secondary to a general medical condition or substance abuse.
  • Ages between 18-65 years old.
  • Patients receiving other psychotropic medications (anti-depressants, mood stabilizers, sedatives, hypnotics) must be on a stable dose for at least 2 weeks before entering the trial.
  • Able to understand and sign an informed consent form.

Exclusion Criteria:

  • Patients suffering from psychotic disorders caused by a general medical condition.
  • Patients having high suicidal risk, as measured by score of 2 or more in CDSS - Calgary Depression Scale for Schizophrenia.
  • Patients suffering from an unstable clinically significant medical condition (endocrine, nutritional, hepatic, urinary).
  • Significant cardiovascular illness, and/or QT prolongation at screening (more then 450 msec for male or 470 msec for female).
  • Patients suffering from a malignancy or neuro-degenerative illness (e.g. Parkinsons' Disease)
  • Patients suffering from organic brain disorders, including epilepsy and mental retardation.
  • Patients suffering from a clinically significant mood disorder.
  • Pregnancy.
  • History of drug or alcohol dependence within the last year.
  • Previous documented non-response to Risperidone.
  • Patients using medicinal products that are contraindicated with sertindole and/or Risperidone.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00480844

Contact: Mark Weiser, Dr 03-5303773

Department of Psychiatry of the Sheba Medical Center Recruiting
Ramat Gan, Tel Hashomer, Israel, 52621
Contact: Mark Weiser, Dr    03-5303773   
Principal Investigator: Mark Weiser, Dr         
Beer-Yaakov Mental Health Center Not yet recruiting
Beer-Yaakov, Israel, 70350
Principal Investigator: Yehuda Abramowitz, Dr         
Kfar Shaul Mental Health Center Not yet recruiting
Jerusalem, Israel, 91060
Principal Investigator: Alexander Teitelbaum, Dr         
Sponsors and Collaborators
Sheba Medical Center
Principal Investigator: Mark Weiser, Dr Shaba Medical Center, Tel-Aviv University Sackler School of Medicine
  More Information

Responsible Party: Prof. Mark Weiser, Sheba Medical Center Identifier: NCT00480844     History of Changes
Other Study ID Numbers: SHEBA-07-4639-JL-CTIL
Study First Received: May 30, 2007
Last Updated: March 24, 2009

Keywords provided by Sheba Medical Center:
cognitive impairment

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents processed this record on April 28, 2017